Determination of vigabatrin in human plasma and urine by high-performance liquid chromatography with fluorescence detection.
A sensitive and specific HPLC method has been developed for the assay of vigabatrin in human plasma and urine. The assay involves derivatization with 4-chloro-7-nitrobenzofurazan, solid-phase extraction on a silica column and isocratic reversed-phase chromatography with fluorescence detection. Aspartam was used as an internal standard. The assay was linear over the concentration range of 0.2-20.0 microg/ml for plasma and 1.0-15.0 microg/ml for urine with a lower limit of detection of 0.1 microg/ml using 0.1 ml of starting volume of the sample. Both the within-day and day-to-day reproducibilities and accuracies were less than 5.46% and 1.6%, respectively. After a single oral dose of 500 mg of vigabatrin, the plasma concentration and the cumulative urinary excretion of the drug were determined.
Erturk
S
S
University of Istanbul, Faculty of Pharmacy, Department of Analytical Chemistry, Beyazit, Turkey.
Aktas
E S
ES
Atmaca
S
S
D000328:Adult; D000927:Anticonvulsants / Q000032:analysis* / Q000097:blood / Q000652:urine; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D005260:Female; D006801:Humans; D008875:Middle Aged; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013050:Spectrometry, Fluorescence; D020888:Vigabatrin / Q000032:analysis* / Q000097:blood / Q000652:urine
D000927:Anticonvulsants; D020888:Vigabatrin